The vice president of the Spanish Group of Genitourinary Oncology (SOGUG) and head of the Medical Oncology Service at the Lucus Augusti University Hospital in Lugo, Dr. Sergio Vázquez Estévez, has urged that genomic sequencing be broadly incorporated into the National Health System (SNS) in order to determine mutations in tumors.
He has insisted that this rollout must be done “in an organized way” and “so that everyone has access,” noting that “we already have funded drugs” for it. His statements come on the occasion of the start of the XVII Scientific Symposium of SOGUG, which is being held in Madrid until Friday, November 20, under the slogan “Marking the future of genitourinary cancer.” Currently, “the determination of mutations varies a bit depending on the autonomous community,” he said, highlighting positively Galicia and the Valencian Community.
Along the same lines, the president of SOGUG and coordinator of the Genitourinary Tumor Unit at the Puerta de Hierro University Hospital in Majadahonda (Madrid), Dr. Aránzazu González del Alba, has emphasized that both communities have “resources and stable funding for that type of strategy and also with the circuits” needed to put it into practice. However, Vázquez Estévez has warned that “there is no national strategy” on sequencing “nor the financing,” despite the fact that the SNS’s Common Portfolio of Services already includes related biomarkers.
The purpose, he added, is “to reach all centers by establishing reference circuits in those communities where it is not yet properly established,” given that it is an essential tool “in order to be able to indicate a treatment.” At present, “it is being done in certain centers that have the potential to do so,” he specified, within the framework of a meeting that brings together more than 400 specialists, mainly medical oncologists.
Advances in bladder, prostate and kidney cancer
The symposium, with participation from national and international experts, will address different topics, including new therapeutic approaches that could allow preserving the bladder in patients with urothelial cancer, as well as the conservation of other organs in prostate, bladder and kidney tumors. In relation to the bladder, SOGUG’s vice president has clarified that it is still an option for the future, given that “it has to be demonstrated in clinical trials,” which are currently “already underway.”
Recent progress, such as combinations of conjugated antibodies and immunotherapy, opens the door to organ preservation and a more finely tuned selection of patients who are candidates for these treatments, through the analysis of circulating tumor DNA and new imaging techniques. All of this is set within a scenario in which the Red Española de Registros de Cáncer (REDECAN) projects 23,929 new diagnoses of urinary bladder cancer, 34,833 of prostate cancer, and 9,165 of kidney cancer in 2026.
Regarding localized bladder disease, Vázquez Estévez has explained that the main advances focus on the arrival of new drugs in the perioperative setting, "before and after cystectomy." He has highlighted that there are "different mechanisms of action" and has celebrated "better results in overall survival," underscoring that patients "live longer and better because these are treatments that are better tolerated than those based on cisplatin-based chemotherapy," in addition to the fact that "they can reach more" people.
Personalized medicine in genitourinary tumors
With regard to advanced disease, the specialist has indicated that "the paradigm of radical treatment has been changed" thanks to "Precision Medicine or Precision Oncology." González del Alba has agreed with this vision and has placed emphasis on the consolidation of personalized medicine in genitourinary tumors, especially prostate cancer. Regarding the latter, he has pointed out that "a whole lot of therapeutic advances have been recorded in the last decade," with special relevance in localized disease with a high risk of metastasis."
He has also referred to kidney cancer, which he has said "is very immunogenic," which is why "new strategies for cellular immunity are being tested." In this context, he has highlighted "how the therapeutic strategy has changed with the arrival of immunotherapy in the first line" and has emphasized that "the challenge is how to treat when patients progress."
The specialists have also advanced other key contents of the meeting, such as the push for teranostics, an approach that combines diagnosis and treatment through molecular tools, and the analysis of the role of the new radioligands, of the therapies aimed at overcoming hormonal resistance, and of the options for hormonal intensification in patients with localized high-risk prostate cancer.
Finally, they have advanced that strategies will be reviewed to maintain the patient’s quality of life and minimize the impact of the disease across its various spheres, as well as the growing influence of artificial intelligence (AI) in the analysis of medical images, clinical data, and molecular information. In any case, the president of SOGUG has specified that, for now, the organization uses AI mainly for the continued training of professionals.